4593 — Healios KK Share Price
0.000.00%
Last trade - 00:00- ¥13bn
- ¥14bn
- ¥121m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.39 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 108.01 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -39.26% | ||
| Return on Equity | -92.83% | ||
| Operating Margin | -3240.5% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 89 | 27 | 41 | 90 | 121 | 1,215 | 1,565 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
HEALIOS K.K. is a Japan-based company mainly engaged in research and development of pharmaceutical products. The Company has compound pharmaceutical products line and induced pluripotent stem cell (iPSC) regenerative medicine product line. The compound pharmaceutical product line contains HLM0021, HLM0022 and HLM0023. The products are ophthalmological surgery adjuvants, mainly contain brilliant blue G-250 (BBG250) which help capsule temporarily safely stained to protect the inner limiting membranes and lens during surgery of vitreous and cataract. The iPSC regenerative medicine product line contains HLCR011 and HLCR012. The products are in the preclinical testing and preparation for trial in Japan, which are candidate of regenerative medicine products. The products are iPS cell derived retinal pigment epithelium (RPE) cell suspension and sheet developed in Japan, United States and Europe.
Directors
- Tadahisa Kagimoto PRE (45)
- Richard Kincaid CFO (45)
- Masanori Sawada VPR (40)
- Koji Abe EXO (61)
- Michihisa Nishiyama EXO (73)
- Kouichi Tamura EXO (65)
- Yoshinari Matsuda DRC (43)
- David Smith DRC (61)
- Michael Alfant IND (60)
- Gregory Bonfiglio IND (69)
- Seigo Kashii IND (68)
- Jun Narimatsu IND (53)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 24th, 2011
- Public Since
- June 16th, 2015
- No. of Shareholders
- 18,740
- No. of Employees
- 64
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 90,130,024
- Address
- 11F, Seiroka Tower, 8-1, Akashi-cho, CHIYODA-KU, 100-0006
- Web
- https://www.healios.co.jp/
- Phone
- +81 345908006
- Auditors
- Deloitte Touche Tohmatsu LLC
Upcoming Events for 4593
Dividend For 4593.T - 0.0000 JPY
Similar to 4593
3-D Matrix
Tokyo Stock Exchange
AnGes
Tokyo Stock Exchange
BrightPath Biotherapeutics Co
Tokyo Stock Exchange
Carna Biosciences
Tokyo Stock Exchange
Chiome Bioscience
Tokyo Stock Exchange
FAQ
What is the Healios KK share price?
As of Today at 19:10 UTC, shares in Healios KK are trading at ¥145. This share price information is delayed by 15 minutes.
How has the Healios KK share price performed this year?
Shares in Healios KK last closed at ¥145 and the price had moved by -52.77% over the past 365 days. In terms of relative price strength the Healios KK share price has underperformed the Nikkei 225 Index by -64.46% over the past year.
What are the analyst and broker recommendations for Healios KK?
The overall consensus recommendation for Healios KK is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Healios KK dividend yield?
Healios KK does not currently pay a dividend.
Does Healios KK pay a dividend?
Healios KK does not currently pay a dividend.
When does Healios KK next pay dividends?
Healios KK does not currently pay a dividend.
How do I buy Healios KK shares?
To buy shares in Healios KK you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Healios KK?
As of the previous close price of ¥145, shares in Healios KK had a market capitalisation of ¥13bn.
Where are Healios KK shares listed?
Here are the trading details for Healios KK:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4593
What kind of share is Healios KK?
Based on an overall assessment of its quality, value and momentum Healios KK is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Healios KK share price forecast for 2024?
The analyst consensus target price for shares in Healios KK is ¥303. That is 108.62% above the last closing price of ¥145.
Analysts covering Healios KK currently have a consensus Earnings Per Share (EPS) forecast of -¥33 for the next financial year.
What is the trend in the Healios KK share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Healios KK. Over the past six months, its share price has underperformed the Nikkei 225 Index by -23.85%.
As of the last closing price of ¥145, shares in Healios KK were trading -23.45% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Healios KK PE Ratio?
The Healios KK PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥145.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Healios KK?
Healios KK's management team is headed by:
- Tadahisa Kagimoto - PRE
- Richard Kincaid - CFO
- Masanori Sawada - VPR
- Koji Abe - EXO
- Michihisa Nishiyama - EXO
- Kouichi Tamura - EXO
- Yoshinari Matsuda - DRC
- David Smith - DRC
- Michael Alfant - IND
- Gregory Bonfiglio - IND
- Seigo Kashii - IND
- Jun Narimatsu - IND